Expert Interviews

The key opinion leaders explore strategies for incorporating continuous glucose monitoring into primary care diabetes management, highlighting essential takeaways from their comprehensive discussion.

Medical experts analyze the case of a 78-year-old woman with diabetes, evaluating the impact of continuous glucose monitoring on her treatment outcomes and overall diabetes management.

The panelists discuss the selection criteria for continuous glucose monitoring (CGM) candidates, identifying patient groups who would derive the greatest benefit from CGM use and those at higher risk of complications without such monitoring.

Key opinion leaders explore the advantages of remote medication adjustments facilitated by distant patient monitoring and the ability to view glucose data from afar, enhancing diabetes care management.

Medical experts in diabetes management examine a real-world case study, providing valuable insights into the clinical impact of continuous glucose monitoring systems and their role in enhancing patient management strategies.

The panel analyzes various continuous glucose monitoring (CGM) methods, detailing the advantages of each approach and sharing their preferred CGM systems for optimal patient care.

Key opinion leaders emphasize the significance of continuous glucose monitoring for diabetes patients, underscoring its advantages in enhancing physician practices and improving patient care strategies.

Key opinion leaders in the management of diabetes delineate the definition of older patients and examine the implications of homeostenosis, a condition that disrupts homeostatic mechanisms in aging individuals.

Medha Munshi, MD, and Javier Morales, MD, FACP, FACE, emphasize the significance of personalized diabetes management, emphasizing age and other patient-specific factors as crucial considerations for optimizing care.

Shagun Bindlish, MD, board member of the ADA, discusses how societal weight-related stigma contributes to mental health challenges faced by women with obesity.

The panel of experts from UCSD concludes the discussion on delaying the onset of stage 3 T1D by providing key takeaways and clinical advice on the treatment of patients with this condition.

Focusing on the utilization of teplizumab, the expert panel from UCSD shares insights in how to select patients for this treatment and provide practical tips for the infusion process, and infusion location options.

The panel reviews the TN-10 trial investigating teplizumab, focusing on patient inclusion criteria, patient outcomes, and adverse reactions.

Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.

Schafer Boeder, MD and Andrea Stallings, PA delve into the intricacies of autoantibody screening tests for T1D with detailed insights on their methodologies, interpretation nuances, and practical analysis considerations.

Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.

Addressing the significance of acting early in T1D care, a group of diabetes experts delve into the impact of delaying intervention during stage 2 of the condition.

Schafer Boeder, MD and his colleagues provide a comprehensive overview of the stages of T1D in patients with diabetes, highlighting the various signs and symptoms associated with each stage.

A panel of experts on diabetes management introduce themselves and provide an overview of the condition, highlighting risk factors, disease burden, and the benefits of collaborative care.

The dual interleukin-4, 13 inhibitor reduced COPD exacerbation rates by as much as 34% for individuals with COPD with type 2 inflammation, Bhatt explains.

Primary care clinicians are essential to maximizing evidence-based midlife care for women, according to Professor of Obstetrics & Gynecology JoAnn Pinkerton, MD.

The novel dual neurokinin-1,3 antagonist reduced VMS after just 1 week of treatment, Pinkerton said, and improved sleep and quality of life, as well. Hear more.

A panel of experts in the management of diabetes share their key takeaways and clinical pearls for the utilization of teplizumab for the delay of onset of type 1 diabetes.

Kent Stoneking Pharm D, CDECS and Marianne Briggs, DNP, FNP-C share their experiences with the dosing regimen and infusion process for teplizumab. This segment offers an in-depth look at the 14-day course of treatment, providing insights into the patient experience and what individuals can expect during this crucial intervention period.

In this discussion, a panel of diabetes management experts examines the groundbreaking potential of teplizumab, the first FDA-approved therapy of its kind, in delaying the onset of T1D stage progression. They discuss its unique mechanism of action and explore its pivotal role in early intervention strategies.

Dr Jennifer D. Goldman and Marianne Briggs, DNP, FNP-C explore the critical role of antibodies in determining T1D progression and emphasize the importance of regular screening. In this segment learn about the four main antibodies pivotal in T1D screening and stage progression.

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, discusses the stages of T1D progression. She emphasizes the risks of delaying intervention in stage 2 T1D, including heightened DKA risk and severe complications, along with potential treatment efficacy reduction and poorer long-term glycemic control.

Kent Stoneking Pharm D, CDECS, shares his personal T1D story and underscores the critical importance of early diagnosis and intervention for this condition. Following his story, Marianne Briggs, DNP, FNP-C, provides invaluable suggestions for identifying individuals at risk for T1D through effective screening methods.

Kashif Latif, MD defines diabetes, shedding light on the pivotal role of B cells. He introduces the concept of diabetes stages and emphasizes the critical importance of early intervention to prevent complications.

A panel of experts in the management of diabetes addresses the profound burden of type 1 diabetes (T1D), emphasizing heightened familial predisposition for this condition. They explore geographic disparities as well as the role of prediabetes in this patient population.